PTEN: Regulation, Signalling and Targeting in Cancer

Dear Colleagues,

PTEN is a tumour suppressor with frequent loss-of-function events documented in sporadic and heritable cancers. It dephosphorylates protein substrates, but also the lipid signalling intermediate PIP3, generated by PI3K, curtailing the Akt pathway. Additionally, PTEN exerts functions independently of its phosphatase activity, via scaffolding partner proteins to form signalosomes. These pleiotropic functions of PTEN enable it to control key biological processes involved in carcinogenesis, including cell proliferation, differentiation, migration and apoptosis. PTEN levels and activity are subjected to fine-tuning, through epigenetic mechanisms, transcription, RNA stability, post-translational modifications, protein–protein interactions and subcellular targeting, which are all susceptible to alteration during carcinogenesis.

We are pleased to invite authors to submit their original or review articles to this Special Issue entitled “PTEN: Regulation, Signalling and Targeting in Cancer". Articles focused on PTEN signalling and (dys)regulation, molecular partners, effector systems and their pathophysiological significance will be considered. Translational studies aimed at monitoring, restoring or substituting PTEN function also fall within the scope of this Special Issue.

This Special Issue aims to provide a resource for researchers interested in: i) different levels of PTEN regulation and function, and the underlying mechanisms/biological impact associated with its dysregulation during carcinogenesis; and ii) in the definition of biomarkers with prognostic value and/or putative targets for precision medicine. We look forward to receiving your contributions.

Dr. Mark G.H. Scott
Dr. Larissa Kotelevets
Dr. Éric Chastre
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.